Skip to main content
Propanc Biopharma, Inc. logo

Propanc Biopharma, Inc. — Investor Relations & Filings

Ticker · PPCB ISIN · US74346N4043 LEI · 549300Q3HY827FNV8Y56 US Professional, scientific and technical activities
Open in API
Filings indexed 412 across all filing types
Latest filing 2021-03-19 Regulatory Filings
Country US United States of America
Listing US PPCB

About Propanc Biopharma, Inc.

https://www.propanc.com/

Propanc Biopharma, Inc. is a clinical-stage company developing cancer treatments focused on preventing tumor recurrence and metastasis. Its lead candidate, PRP, is a pancreatic proenzyme formulation designed to target and eradicate cancer stem cells. The therapeutic approach aims to suppress tumor progression by controlling cancer cell migration, inhibiting the formation of tumor blood vessels, and inducing cell death. The company's primary focus is on developing long-term therapies for patients with solid tumors, such as pancreatic cancer.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2021
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a convertible promissory note, details of the note, and related financial obligations. It also references the filing of exhibits related to the agreement. The document is not a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a transcript, presentation, or voting result. It is a regulatory filing announcing a significant financing transaction and related agreements. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (11,488 characters) and detailed content support this classification with high confidence.
2021-03-19 English
Interim / Quarterly Report 2021
Interim / Quarterly Report Q2 2021
2021-02-12 English
Capital/Financing Update 2021
Capital/Financing Update Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a convertible promissory note and securities purchase agreement, detailing terms of the financing transaction. It includes information about the note's terms, conversion rights, events of default, and related agreements. This is a disclosure of a financing event rather than a full financial report or earnings release. The document is not an annual or quarterly report, audit report, or earnings release. It is not a proxy, voting result, or management change announcement. The primary focus is on a capital raising transaction and related financing terms. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support a high confidence in this classification.
2021-01-11 English
Board/Management Information 2020
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated December 23, 2020, for Propanc Biopharma, Inc. The content focuses on changes in the company's officers and board of directors: resignation of the CFO, appointment of a new CFO, and election of a new board member. It includes details about the director agreement and indemnification agreement. There are no financial statements or detailed financial performance data presented. The primary subject is management changes, which aligns with the Board/Management Information category. The document length is 7464 characters, sufficient to contain substantive information about management changes. Therefore, the appropriate classification is MANG (Board/Management Information).
2020-12-30 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a securities purchase agreement and issuance of a convertible promissory note, including terms of the note, interest, conversion rights, and default provisions. It also references the creation of a direct financial obligation and unregistered sales of equity securities. The document is not a full financial report but an announcement of a financing transaction and related agreements. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length (8131 characters) and detailed description of the financing terms support this classification with high confidence.
2020-12-16 English
Capital/Financing Update 2020
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement involving a convertible promissory note, detailing terms of the note, events of default, and related financial obligations. It does not contain comprehensive financial statements or detailed financial performance data typical of annual or interim reports. Instead, it focuses on a financing transaction and related contractual terms. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document length is over 12,000 characters, indicating it is a substantive filing rather than a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2020-12-07 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.